SCM
NGM

Soleus Capital Management’s NGM Biopharmaceuticals, Inc. Common Stock NGM Stock Holding History

Soleus Capital Management’s Portfolio NGM Stock Details NGM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-13,000
Closed -$230K – 81
2021
Q4 		$230K Sell
13,000
-28,000
-68% -$537K 0.02% 66
2021
Q3 		$862K Buy
+41,000
New +$903K 0.13% 66

Other funds holding NGM

CG
Column Group San Francisco, California $101M AUM 290.34% 1-Year Est. Return
RCP
Rho Capital Partners New York $20.4M AUM
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SG
StepStone Group La Jolla, California $207M AUM 12.33% 1-Year Est. Return
PIM
Ponoi II Management San Francisco, California $38.3M AUM 32.02% 1-Year Est. Return
PM
Ponoi Management San Francisco, California $73.2M AUM 23.44% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Soleus Capital Management's NGM Position: Q1 2022 in Review

Soleus Capital Management sold out of NGM Biopharmaceuticals, Inc. Common Stock (NGM) in Q1 2022, closing a stake of 13,000 shares — an estimated $230K sold.

Soleus Capital Management first reported a position in NGM in Q3 2021 and held it in 2 quarters. The position peaked at $862K in Q3 2021. 114 funds tracked by Wall St. Rank hold NGM as of Q1 2022.

  • Soleus Capital Management reported no remaining NGM Biopharmaceuticals, Inc. Common Stock position as of Q1 2022 after selling out during the quarter.
  • Soleus Capital Management sold 13,000 NGM Biopharmaceuticals, Inc. Common Stock shares in Q1 2022, an estimated $230K.
  • Soleus Capital Management first reported a position in NGM Biopharmaceuticals, Inc. Common Stock in Q3 2021 and held it in 2 quarters.
  • Soleus Capital Management's NGM Biopharmaceuticals, Inc. Common Stock position peaked at $862K in Q3 2021.
  • 114 funds tracked by Wall St. Rank held NGM Biopharmaceuticals, Inc. Common Stock as of Q1 2022.

Based on Soleus Capital Management's 13F filing for Q1 2022, filed 16 May 2022.